Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial.

Cytokine storm is the most prominent hallmark in patients with coronavirus disease 2019 (COVID-19) that stimulates the free radical storm, both of which induce an overactive immune response during viral infection. We hypothesized that owning to its radical-scavenging and anti-inflammatory properties, Edaravone could reduce multi-organ injury, clinical complications, and mortality in severe COVID-19 cases. This single-center randomized clinical trial was accompanied in the intensive care units (ICUs) of the teaching hospital of Tabriz University of Medical Sciences to evaluate the effect of Edaravone on the outcome of patients with severe COVID-19. Thirty-eight patients admitted to ICU were included and randomized into two control and intervention arms. Patients in the intervention group received 30 mg Edaravone by slow intravenous infusion for three days in addition to receiving national therapy. The primary outcome was the need for intubation, the intubation length, and mortality rate. Secondary endpoints were clinical improvement. Edaravone administration improved the primary outcomes; it decreased the need for endotracheal intubation and mechanical ventilation [10.52% (n = 2) versus 42.1% (n = 8); p = 0.03] and intubation length [3 (1-7) versus 28 (4-28), p = 0.04] compared to control group. Baseline characteristics and laboratory tests were similar between the studied groups. No marked differences were observed in secondary endpoints (p > 0.05). Administration of Edaravone could decrease the need for mechanical ventilation and length of intubation in severe COVID-19 patients admitted to ICU.

Burtonian line in a patient with occupational lead poisoning.

More attention of the medical staff to this sign can lead to faster diagnosis and timely treatment of patients.

Evaluation of Children Quality of Life after Serous Otitis Media Surgery.

Introduction: Otitis media with effusion is a common childhood disease diagnosed with the accumulation of serous fluid or mucous in the middle ear. If not treated, the sustainable effusion leads to change and destruction of middle ear structures. One of the most successful treatment methods is myringotomy and ventilation tube insertion, which leads to improvement of patients' quality of life. The aim of this study was to evaluate children's quality of life after inserting ventilation tubes. Methods: This prospective cross-sectional study examined the quality of life of the children suffering from otitis media with sustainable effusion, who were candidates for ventilation tube insertion. Otitis Media outcome-22 (OMO -22) questionnaire, was used to record the patients' problems in a 12-week period before and after surgery. Results: In this study, 70 patients, including 43 (61.4%) boys and 27 (38.6%) girls (1y-13y), who completed the questionnaire, were studied. Treatment with ventilation tubes improved many physical symptoms of the hearing loss along with speech and behavioral symptoms. A significant reduction was observed in the number of physician visits and the use of antibiotics for ear problems. Conclusion: Ventilation tube insertion not only reduced the symptoms of otitis media with effusion, but also improved the children's quality of life.